NEW ZeALAND DATA SHEET

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT
IMATIS 100 mg & 400 mg Film Coated Tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance
Each film coated tablet contains 100 mg or 400 mg imatinib (as mesilate).

Excipients:
For full list of excipients see 6.1.

3. PHARMACEUTICAL FORM
Film Coated Tablets.

100 mg tablets, divisible: Very dark yellow to brownish orange film coated tablets, round, biconvex and score on one side.
400 mg tablets, not divisible: Very dark yellow to brownish orange, ovaloid film coated tablets.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
IMATIS is indicated for the
• Treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) (for pediatric use see section 4.2).
• Treatment of adult and pediatric patients with Ph+CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy (for pediatric use see section 4.2).
• Treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.
• Treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.
• Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
• Treatment of adult patients with systemic mastocytosis (SM) without the D816V c-KIT mutation or with c-Kit mutational status unknown.
• Treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL).
• Treatment of adult patients with KIT+ (CD117) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
• Adjuvant treatment of adult patients following resection of KIT+GIST.
• Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).

4.2 Posology and method of administration
Therapy should be initiated by a physician experienced in the treatment of patients with hematological malignancies and malignant sarcomas, as appropriate.
Monitoring of response to IMATIS therapy in Ph+ CML patients should be performed routinely and when therapy is modified, to identify suboptimal response, loss of response to therapy, poor patient compliance, or possible drug-drug interaction. Results of monitoring should guide appropriate CML management.

**Dosage in CML**
The recommended dosage of IMATIS is 400 mg/day for adult patients in chronic phase CML and 600 mg/day for patients in accelerated phase or blast crisis. Dose increase from 400 mg to 600 mg or 800 mg in patients with chronic phase disease, or from 600 mg to a maximum of 800 mg daily in patients in accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory hematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved hematological and/or cytogenetic response.

**Dosage in Ph+ ALL**
The recommended dose of IMATIS is 600 mg/day for adult patients with Ph+ ALL.

**Dosage in MDS/MPD**
The recommended dose of IMATIS is 400 mg/day for adult patients with MDS/MPD.

**Dosage in SM**
The recommended dose of IMATIS is 400 mg/day for adult patients with SM without the D816V c-Kit mutation or mutational status unknown or not responding satisfactorily to other therapies. For patients with SM associated with eosinophilia, a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR-alpha, a starting dose of 100 mg/day is recommended. A dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.

**Dosage in HES/CEL**
The recommended dose of IMATIS is 400 mg/day for adult patients with HES/CEL. For HES/CEL patients with demonstrated FIP1L1-PDGFR-alpha fusion kinase, a starting dose of 100 mg/day is recommended. A dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy. Treatment should be continued as long as the patient continues to benefit.

**Dosage in GIST**
The recommended dose of IMATIS is 400 mg/day for adult patients with unresectable and/or metastatic, malignant GIST. A dose increase from 400 mg to 600 mg or 800 mg for patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy. The recommended dose of IMATIS is 400 mg/day for the adjuvant treatment of adult patients following resection of GIST. The recommended minimum treatment duration is 36 months. In the adjuvant setting the optimal treatment duration with IMATIS is not known.

**Dosage in DFSP**
The recommended dose of IMATIS is 800 mg/day for adult patients with DFSP.

**Dose adjustments for adverse drug reactions**

**Non-hematological adverse drug reactions**
If a severe non-hematological adverse drug reaction develops with IMATIS use, treatment must be withheld until the event has resolved. Thereafter, treatment can be resumed as appropriate depending on the initial severity of the event. If elevations in bilirubin >3×institutional upper limit of normal (IULN) or in liver transaminases >5×IULN
occur, IMATIS should be withheld until bilirubin levels have returned to a <1.5×IULN and transaminase levels to <2.5×IULN. Treatment with IMATIS may then be continued at a reduced daily dose. In adults the dose should be reduced from 400 to 300 mg, or from 600 to 400 mg, or from 800 mg to 600 mg, and in children from 340 to 260 mg/m²/day.

**Hematological adverse drug reactions**

Dose reduction or treatment interruption for severe neutropenia and thrombocytopenia are recommended as indicated in the table below.

**Dose adjustments for neutropenia and thrombocytopenia**

<table>
<thead>
<tr>
<th>Condition</th>
<th>ANC &lt;1.0×10⁹/L and/or platelets &lt;50×10⁹/L</th>
<th>Action 1</th>
<th>Action 2</th>
<th>Action 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>SM associated with eosinophilia and HES with FIP1L1-PDGFR-alpha fusion kinase (starting dose 100 mg)</td>
<td></td>
<td>Stop IMATIS treatment until ANC ≥1.5×10⁹/L and platelets ≥75×10⁹/L.</td>
<td>Resume treatment with IMATIS at previous dose (i.e. before severe adverse reaction).</td>
<td>In the event of recurrence of ANC &lt;1.0×10⁹/L and/or platelets &lt;50×10⁹/L, repeat step 1 and resume IMATIS at reduced dose of 300 mg.</td>
</tr>
<tr>
<td>Chronic phase CML, SM, HES (starting dose 400 mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pediatric chronic phase CML (at dose 340 mg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accelerated phase CML and blast crisis and Ph+ ALL (starting dose 600 mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DFSP (starting dose 800 mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Additional information on special populations**

**Children**

There is no experience with the use of IMATIS in children with CML below 2 years of age. There is very limited experience with the use of IMATIS in children in other indications. Dosing in children should be on the basis of body surface area (mg/m²). The dose of 340 mg/m² daily is recommended for children with chronic phase and advanced phase CML (not to exceed the total dose of 600 mg/m²/day).
mg daily). Treatment can be given as a once daily dose or alternatively the daily dose may be split into two administrations – one in the morning and one in the evening (see Section 5.1).

**Hepatic insufficiency**
Imatinib is mainly metabolized by the liver. Patients with mild, moderate or severe liver dysfunction should be given the minimum recommended dose of 400 mg daily. The dose can be reduced if not tolerated (see Sections 4.4, 4.8, 5.1 and 5.2).

**Renal insufficiency**
Imatinib and its metabolites are not significantly excreted via the kidney. Patients with renal dysfunction or on dialysis could be given the minimum recommended dose of 400 mg daily as starting dose. (see Sections 5.1 and 5.2). However, in these patients caution is recommended. The dose can be reduced if not tolerated. If tolerated, the dose can be increased for lack of efficacy (see section 4.4).

**Elderly patients**
No significant age related pharmacokinetic differences have been observed in adult patients in clinical trials which included over 20% of patients age 65 and older. No specific dose recommendation is necessary in the elderly.

**Method of administration**
The prescribed dose should be administered orally with a meal and a large glass of water to minimize the risk of gastrointestinal disturbances. Doses of 400 mg or 600 mg should be administered once daily, whereas a daily dose of 800 mg should be administered as 400 mg twice a day, in the morning and in the evening.

For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of water or apple juice. The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 ml for a 100 mg tablet, and 200 ml for a 400 mg tablet) and stirred with a spoon. The suspension should be administered immediately after complete disintegration of the tablet(s).

Treatment should be continued as long as the patient continues to benefit.

**4.3 Contraindications**
Hypersensitivity to imatinib or to any of the excipients.

**4.4 Special warnings and precautions for use**
When IMATIS is co-administered with other medications, there is a potential for drug interactions. Caution should be used when taking IMATIS with rifampicin or other strong CYP3A4 inducers, ketoconazole or other strong CYP3A4 inhibitors, CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporin or pimozide) or CYP2C9 substrates with a narrow therapeutic window (e.g. warfarin and other coumarin derivatives) (see section 4.5).

**Hypothyroidism**
Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with IMATIS. TSH levels should be closely monitored in such patients.

**Hepatotoxicity**
In patients with hepatic dysfunction (mild, moderate or severe), peripheral blood counts and liver enzymes should be carefully monitored (see sections 4.2, 4.8, 5.1)

When IMATIS is combined with high dose chemotherapy regimens, transient liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Additionally, there have been uncommon reports of acute liver failure. Monitoring of hepatic function is recommended in circumstances where IMATIS is combined with chemotherapy regimens also known to be associated with hepatic dysfunction (see section 9 Adverse drug reactions).

**Fluid retention**
Occurences of severe fluid retention (pleural effusion, edema, pulmonary edema, ascites, and superficial
edema) have been reported in approximately 2.5% of newly diagnosed CML patients taking IMATIS. Therefore, it is recommended that patients be weighed regularly. An unexpected rapid weight gain should be carefully investigated and if necessary appropriate supportive care and therapeutic measures should be undertaken. In clinical trials, there was an increased incidence of these events in elderly patients and those with a prior history of cardiac disease.

**Patients with cardiac disease or renal failure**

Patients with cardiac disease, risk factors for cardiac failure or history of renal failure should be monitored carefully and any patient with signs or symptoms consistent with cardiac or renal failure should be evaluated and treated.

In patients with hypereosinophilic syndrome (HES) with occult infiltration of HES cells within the myocardium, isolated cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degradation upon the initiation of IMATIS therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding IMATIS. Myelodysplastic (MDS)/myeloproliferative (MPD) diseases and systemic mastocytosis might be associated with high eosinophil levels. Performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/CEL, and in patients with MDS/MPD or SM associated with high eosinophil levels. If either is abnormal, the prophylactic use of systemic steroids (1 to 2 mg/kg) for one to two weeks concomitantly with IMATIS should be considered at the initiation of therapy.

**Gastrointestinal hemorrhage**

In the Phase III GIST studies in patients with unresectable or metastatic malignant GIST 211 patients (12.9%) reported Grade 3/4 hemorrhage at any site. In the Phase II GIST study in patients with unresectable or metastatic malignant GIST (study B2222), eight patients (5.4%) were reported to have had gastrointestinal (GI) hemorrhage and four patients (2.7%) were reported to have had hemorrhages at the site of tumor deposits. The tumor hemorrhages have been either intra-abdominal or intra-hepatic, depending on the anatomical location of tumor lesions. GI sites of tumor may have contributed to GI bleeding in this reported patient population. In addition, gastric antral vascular ectasia (GAVE), a rare cause of GI hemorrhage, has been reported in post-marketing experience in patients with CML, ALL, and other diseases. Patients should therefore be monitored for gastrointestinal symptoms at the start of and during therapy with IMATIS. When needed, IMATIS discontinuation may be considered (see section 4.8).

**Tumor lysis syndrome**

Cases of tumor lysis syndrome (TLS) have been reported in patients treated with IMATIS. Due to possible occurrence of TLS, correction of clinically significant dehydration and treatment of high uric acid levels are recommended prior to initiation of IMATIS (see section 4.8).

**Hepatitis B reactivation**

Reactivation of hepatitis B can occur in patients who are chronic carriers of this virus after receiving a BCR-ABL tyrosine kinase inhibitor (TKI), such as imatinib. Some cases of hepatitis B reactivation involving drugs of the BCR-ABL TKI class resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome (see Section 4.8).

Patients should be tested for hepatitis B infection before initiating treatment with imatinib. Patients currently on imatinib should have baseline testing for hepatitis B infection in order to identify chronic carriers of the virus. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for hepatitis B infection during treatment. Carriers of hepatitis B virus who require treatment with imatinib should be closely monitored for signs and symptoms of active hepatitis B infection throughout therapy and for several months following termination of therapy.

**Laboratory tests**

Complete blood counts must be performed regularly during therapy with IMATIS. Treatment of CML patients with IMATIS has been associated with neutropenia or thrombocytopenia. However, the occurrence of these cytopenias is dependent on the stage of the disease being treated and they were more frequent in
patients with accelerated phase CML or blast crisis as compared to patients with chronic phase CML. Treatment with IMATIS may be interrupted or the dose be reduced, as recommended in section 4.2. Liver function (transaminases, bilirubin, alkaline phosphatase) should be monitored regularly in patients receiving IMATIS. As recommended in section 4.2, non-hematological adverse drug reactions, these laboratory abnormalities should be managed with interruption and/or dose reduction of the treatment with IMATIS.

IMATIS and its metabolites are not excreted via the kidney to a significant extent. Creatinine clearance (CrCL) is known to decrease with age, and age did not significantly affect IMATIS kinetics. In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in these patients. There is no correlation between imatinib exposure and the degree of renal impairment, as classified by the measurement of creatinine clearance (CrCL), between patients with mild (CrCL: 40 to 59 ml/min) and severe (CrCL: <20 ml/min) renal impairment. However, as recommended in section 4.2, the starting dose of imatinib can be reduced if not tolerated.

**Children and adolescents**
There have been case reports of growth retardation occurring in children and pre-adolescents receiving IMATIS. The long term effects of prolonged treatment with IMATIS on growth in children are unknown. Therefore, close monitoring of growth in children under IMATIS treatment is recommended (see section 4.8).

**4.5 Interaction with other medicinal products and other forms of interaction**

**Drugs that may alter imatinib plasma concentrations**

**Drugs that may increase imatinib plasma concentrations**
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin) could decrease metabolism and increase imatinib concentrations. There was a significant increase in exposure to imatinib (the mean $C_{\text{max}}$ and AUC of imatinib rose by 26% and 40%, respectively) in healthy subjects when it was coadministered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering IMATIS with inhibitors of the CYP3A4 family.

**Drugs that may decrease imatinib plasma concentrations**
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or hypericum perforatum, also known as St. John’s Wort) could increase plasma exposure to IMATIS. Pretreatment of 14 healthy volunteers with multiple doses of rifampin, 600 mg daily for 8 days, followed by a single 400 mg dose of IMATIS, increased IMATIS oral-dose clearance by 3.8-fold (90% confidence interval = 3.5- to 4.3-fold), which represents mean decreases $C_{\text{max}}$, AUC(0-24) and AUC(0-∞) by 54%, 68% and 74%, of the respective values without rifampin treatment. Similar results were observed in patients with malignant gliomas treated with IMATIS while taking enzyme-inducing anti-epileptic drugs (EIAEDs) such as carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, and primidone. The plasma AUC for imatinib decreased by 73% compared to patients not on EIAEDs. In two published studies, concomitant administration of IMATIS and a product containing St. John’s wort led to a 30 to 32% reduction in the AUC of IMATIS. In patients where rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered.

**Drugs that may have their plasma concentration altered by IMATIS**
IMATIS increases the mean $C_{\text{max}}$ and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by IMATIS. Therefore, caution is recommended when administering IMATIS with CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporin or pimozone). IMATIS may increase plasma concentration of other CYP3A4 metabolized drugs (e.g. triazolobenzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.). IMATIS also inhibits CYP2C9 and CYP2C19 activity in vitro. PT prolongation was observed following co-
administration with warfarin. When giving coumarins, short-term PT monitoring is therefore necessary at the start and end of IMATIS therapy and when altering the dosage. Alternatively, the use of low-molecular weight heparin should be considered.

In vitro, IMATIS inhibits the cytochrome P450 isoenzyme CYP2D6 activity at concentrations similar to those that affect CYP3A4 activity. IMATIS at 400 mg twice daily had a weak inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol $C_{\text{max}}$ and AUC being increased by approximately 23%. Co-administration of IMATIS with CYP2D6 substrates, such as metoprolol, does not seem to be a risk factor for drug-drug interactions and dose adjustment may not be necessary.

In vitro, IMATIS inhibits the acetaminophen O-glucuronidate pathway (Ki 58.5 microM). Co-administration of IMATIS (400 mg/day for eight days) with paracetamol (1000 mg single dose on day eight) in patients with CML did not result in any changes in the pharmacokinetics of paracetamol. IMATIS pharmacokinetics was not altered in the presence of single-dose paracetamol.

There is no PK or safety data on the concomitant use of IMATIS at doses >400 mg/day or the chronic use of concomitant paracetamol and IMATIS.

### 4.6 Pregnancy and lactation

**General advice:**

Pregnancy category is D

**Women of child-bearing potential**

Women of childbearing potential must be advised to use highly effective contraception during treatment. Highly effective contraception is a method of birth control which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly.

**Pregnancy**

Studies in animals have shown reproductive toxicity (see section 13 Non-clinical safety data). There are no clinical trials on the use of IMATIS in pregnant women. There have been post-market reports of spontaneous abortions and infant congenital anomalies from women who have taken IMATIS. IMATIS should be used during pregnancy only if the expected benefit outweighs the potential risk to the fetus. If it is used during pregnancy, the patient must be informed of the potential risk to the fetus.

**Breast-feeding**

Both imatinib and its active metabolite can be distributed into human milk. The milk plasma ratio was determined to be 0.5 for imatinib and 0.9 for the metabolite, suggesting greater distribution of the metabolite into the milk. Considering the combined concentration of imatinib and of the metabolite and the maximum daily milk intake by infants the total exposure would be expected to be low (~10% of a therapeutic dose). However, since the effects of low-dose exposure of the infant to imatinib are unknown, women taking IMATIS should not breast feed.

**Fertility**

Human studies on male patients receiving IMATIS and its effect on male fertility and spermatogenesis have not been performed. Male patients concerned about their fertility on IMATIS treatment should consult with their physician (see section 13 Non-clinical safety data).

### 4.7 Effects on ability to drive and use machines

Reports of motor vehicle accidents have been received in patients receiving IMATIS. While most of these reports are not suspected to be caused by IMATIS, patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with IMATIS. Therefore, caution should be recommended when driving a car or operating machinery.

### 4.8 Undesirable effects

**Summary of the safety profile**

The overall safety profile of IMATIS in human clinical use has been well-characterized through more than
12 years of IMATIS experience. During clinical development, the majority of patients experienced adverse events at some point in time. The most frequently reported ADRs (>10%) were neutropenia, thrombocytopenia, anemia, headache, dyspepsia, edema, weight increased, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue, and abdominal pain. Events were of mild to moderate grade, and only 2 to 5% of patients permanently discontinued therapy due to drug-related events.

The differences in the safety profile between Ph+ leukemias and solid tumors are a higher incidence and severity of myelosuppression in Ph+ leukemias, and GI and intra-tumoral hemorrhages in GIST patients and are probably due to disease-related factors. Myelosuppression, GI adverse events, edema, and rashes are common between these two patient populations. Other GI conditions, such as gastrointestinal obstruction, perforation and ulceration, appear to be more indication-specific. Other prominent adverse events that have been observed after exposure to IMATIS, and which may be causally related, include hepatotoxicity, acute renal failure, hypophosphatemia, severe respiratory adverse reactions, and tumor lysis syndrome and growth retardation in children.

Depending on severity of events, dose adjustment may be required. In very few cases will the medication have to be discontinued based on ADRs. Adverse reactions (Table 1 and Table 2) are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10,000, <1/1000); very rare (<1/10,000), including isolated reports. Adverse reactions and their frequencies reported in Table 1 are based on the registration studies for CML and GIST.

### Table 1 - Adverse reactions in studies for CML and GIST

<table>
<thead>
<tr>
<th>Infections and infestations</th>
<th>Uncommon: Herpes zoster, herpes simplex, nasopharyngitis, pneumonia, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare: Fungal infection</td>
<td></td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Very common: Neutropenia, thrombocytopenia, anemia</td>
</tr>
<tr>
<td>Common: Pancytopenia, febrile neutropenia</td>
<td></td>
</tr>
<tr>
<td>Uncommon: Thrombocythemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy</td>
<td></td>
</tr>
<tr>
<td>Rare: Hemolytic anemia</td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Common: Anorexia</td>
</tr>
<tr>
<td>Uncommon: Hypokalemia, increased appetite, hypophosphatemia, decreased appetite, dehydration, gout, hyperuricemia, hypercalcemia, hyperglycemia, hyponatremia</td>
<td></td>
</tr>
<tr>
<td>Rare: Hyperkalemia, hypomagnesaemia</td>
<td></td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Common: Insomnia</td>
</tr>
<tr>
<td>Uncommon: Depression, libido decreased, anxiety</td>
<td></td>
</tr>
<tr>
<td>Rare: Confusional state</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Very common: Headache</td>
</tr>
<tr>
<td>Common: Dizziness, paresthesia, taste disturbance, hypoesthesia</td>
<td></td>
</tr>
<tr>
<td>Uncommon: Migraine, somnolence, syncope, peripheral neuropathy, memory impairment, sciatica, restless leg syndrome, tremor, cerebral hemorrhage</td>
<td></td>
</tr>
<tr>
<td>Rare: Increased intracranial pressure, convulsions, optic neuritis</td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Common: Eyelid edema, lacrimation increased, conjunctival hemorrhage, conjunctivitis, dry eye, blurred vision</td>
</tr>
</tbody>
</table>
Uncommon: Eye irritation, eye pain, orbital edema, scleral hemorrhage, retinal hemorrhage, blepharitis, macular edema
Rare: Cataract, glaucoma, papilledema

Ear and labyrinth disorders
Uncommon: Vertigo, tinnitus, hearing loss

Cardiac disorders
Uncommon: Palpitations, tachycardia, cardiac failure congestive³, pulmonary edema
Rare: Arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris, pericardial effusion

Vascular disorders⁴
Common: Flushing, hemorrhage
Uncommon: Hypertension, hematoma, subdural hematoma, peripheral coldness, hypotension, Raynaud's phenomenon

Respiratory, thoracic and mediastinal disorders
Common: Dyspnea, epistaxis, cough
Uncommon: Pleural effusion⁵, pharyngolaryngeal pain, pharyngitis
Rare: Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary hemorrhage

Gastrointestinal disorders
Very common: Nausea, diarrhea, vomiting, dyspepsia, abdominal pain
Common: Flatulence, abdominal distension, gastro-esophageal reflux, constipation, dry mouth, gastritis
Uncommon: Stomatitis, mouth ulceration, gastrointestinal hemorrhage, eructation, melena, esophagitis, ascites, gastric ulcer, hematemeses, cheilitis, dysphagia, pancreatitis
Rare: Colitis, ileus, inflammatory bowel disease

Hepatobiliary disorders
Common: Increased hepatic enzymes
Uncommon: Hyperbilirubinemia, hepatitis, jaundice
Rare: Hepatic failure⁹, hepatic necrosis⁹

Skin and subcutaneous tissue disorders
Very common: Periorbital edema, dermatitis/eczema/rash
Common: Pruritus, face edema, dry skin, erythema, alopecia, night sweats, photosensitivity reaction
Uncommon: Rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, dermatitis exfoliative, onycholysis, folliculitis, petechiae, psoriasis, purpura, skin hyperpigmentation, bullous eruptions
Rare: Acute febrile neutrophilic dermatosis (Sweet's syndrome), nail discoloration, angioneurotic edema, rash vesicular, erythema multiforme, leucocytoclastic vasculitis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis (AGEP).

Musculoskeletal, connective tissue and bone disorders
Very common: Muscle spasm and cramps, musculoskeletal pain including myalgia³, arthralgia, bone pain
Common: Joint swelling
Uncommon: Joint and muscle stiffness
Rare: Muscular weakness, arthritis

Renal and urinary disorders
Uncommon: Renal pain, hematuria, renal failure acute, urinary frequency increased
Reproductive system and breast disorders

*Uncommon*: Gynecomasty, erectile dysfunction, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, breast enlargement, scrotal edema

General disorders and administration site conditions

*Very common*: Fluid retention and edema, fatigue

*Common*: Weakness, pyrexia, anasarca, chills, rigors

*Uncommon*: Chest pain, malaise

Investigations

*Very common*: Weight increased

*Common*: Weight decreased

*Uncommon*: Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase increased

*Rare*: Blood amylase increased

1. Pneumonia was reported most commonly in patients with transformed CML and in patients with GIST.
2. Headache was the most common in GIST patients.
3. On a patient-year basis, cardiac events including congestive heart failure were more commonly observed in patients with transformed CML than in patients with chronic CML.
4. Flushing was most common in GIST patients and bleeding (hematoma, hemorrhage) was most common in patients with GIST and with transformed CML (CML-AP and CML-BC).
5. Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML.
6. Abdominal pain and gastrointestinal hemorrhage were most commonly observed in GIST patients.
7. Musculoskeletal pain and related events were more commonly observed in patients with CML than in GIST patients.
8. Some fatal cases of hepatic failure and hepatic necrosis have been reported.

The following types of ADRs have been reported from post-marketing experience and from additional clinical studies with IMATIS. They include spontaneous case reports as well as serious ADRs from smaller or ongoing clinical studies and the expanded access programmes. Because these ADRs are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to IMATIS exposure.

### Table 2 Adverse reactions from Post-marketing reports

<table>
<thead>
<tr>
<th>Infections and Infestations</th>
<th>Not known:</th>
<th>Hepatitis B reactivation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous system disorders</td>
<td><em>Uncommon</em>:</td>
<td>Cerebral edema</td>
</tr>
<tr>
<td>Eye disorders</td>
<td><em>Rare</em>:</td>
<td>Vitreous hemorrhage</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td><em>Rare</em>:</td>
<td>Pericarditis, cardiac tamponade</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td><em>Uncommon</em>:</td>
<td>Thrombosis/embolism</td>
</tr>
<tr>
<td></td>
<td><em>Very rare</em>:</td>
<td>Anaphylactic shock</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td><em>Uncommon</em>:</td>
<td>Acute respiratory failure(^1), interstitial lung disease</td>
</tr>
</tbody>
</table>
Gastrointestinal disorders

*Uncommon:* Ileus/intestinal obstruction, tumor hemorrhage/tumor necrosis, gastrointestinal perforation

*Rare:* Diverticulitis, gastric antral vascular ectasia (GAVE)

Skin and subcutaneous tissue disorders

*Uncommon:* Palmar-plantar erythrodysesthesia syndrome

*Rare:* Lichenoid keratitis, lichen planus

*Very rare:* Toxic epidermal necrolysis

*Not known:* Drug rash with eosinophilia and systemic symptoms (DRESS)

Musculoskeletal and connective tissue disorders

*Very common:* Musculoskeletal pain upon treatment discontinuation (including myalgia, pain in extremity, arthralgia, bone pain, spinal pain)

*Rare:* Avascular necrosis/hip osteonecrosis, rhabdomyolysis/myopathy

*Unknown:* Growth retardation in children

Reproductive disorders

*Very rare:* Hemorrhagic corpus luteum/hemorrhagic ovarian cyst

Neoplasm benign, malignant and unspecified (including cysts and polyps)

*Rare:* Tumor lysis syndrome

1. Fatal cases have been reported in patients with advanced disease, severe infections, severe neutropenia and other serious concomitant conditions

2. Some fatal cases of gastrointestinal perforation have been reported

Description of selected Adverse Drug Reactions

Myelosuppression

Myelosuppression is very common in cancer patients treated with IMATIS. Myelosuppression, thrombocytopenia, neutropenia and anemia were the most frequently reported Grade 3 and 4 laboratory abnormalities. Overall, myelosuppression experienced with IMATIS in CML patients was generally reversible and in most patients did not result in dose interruption or dose reduction. Few patients required drug discontinuation. Other events of pancytopenia, lymphopenia and bone marrow depression have also been reported.

Hematologic depression appeared greatest at the highest doses and also appeared to be dependent on stage of CML disease, with Grade 3 or 4 neutropenia and thrombocytopenia between 4 and 6 times higher in blast and accelerated phase (44% and 63%, respectively) as compared to newly diagnosed patients in CP CML (16.7% and 8.9%, respectively). These events can usually be managed with either a dose reduction or interruption, but they rarely require discontinuation of treatment with IMATIS. The incidence of hematologic toxicities is less in patients with solid tumors (i.e., GIST) than in patients with Ph+ leukemias, with Grade 3/4 neutropenia and thrombocytopenia occurring approximately 10% and 1%, respectively.

Hemorrhage

CNS and GI hemorrhages are not uncommon in CML patients with compromised marrow function at baseline. Hemorrhages are well-recognized part of the disease complications in an acutely ill population of leukemic patients, and may result from thrombocytopenia, or less commonly, platelet dysfunction. However, not all patients experiencing CNS and GI hemorrhages during therapy with imatinib are thrombocytopenic. The most common manifestation of clinically significant bleeding was GI hemorrhage, which occurred most commonly in advanced CML patients and in metastatic GIST patients, where bleeding might occur as part of the underlying disease due to tumor bleeding from tumor hemorrhage/tumor necrosis. In first line CML and in adjuvant GIST setting, the observed frequencies of GI hemorrhage were generally the lowest. Gastric antral vascular ectasia (GAVE) is also rarely reported with IMATIS use in the post-marketing setting.

Edema and Fluid Retention

DEVATIS LIMITED Property-Strictly confidential

Page 11/31

Version: NZ-V01/June 2017
Edema is a common toxicity of imatinib appearing in greater than 50% of all patients across all indications. Edema is dose-related and there appears to be a correlation with its occurrence and plasma levels. The most common manifestation is periorbital edema and somewhat less common is lower extremity edema. Specific therapy is not usually required. Other fluid retention events occur much less commonly, but due to the location of the anatomic site may be potentially serious. The most frequent fluid retention event was pleural effusion, most commonly observed in advanced CML and metastatic GIST patients. The frequency of cardiac failure was generally low in patients with edema and fluid retention. It was higher in advanced CML than in other groups. This could be explained by the worse medical condition of advanced CML patients. The same trend was observed for renal failure in patients with edema and fluid retention.

In a clinical study, the frequency of events suggesting congestive heart failure was 1.5% on imatinib vs. 1.1% on IFN-alpha in patients with newly-diagnosed CML. The frequency was appreciably higher in patients with transformed CML (accelerated phase or blast crisis), higher age, or with a baseline hemoglobin of less than 8 g/dl. Across all indications a higher frequency of CHF events observed in patients with CML than in patients with GIST might indicate differences of some of these disease-related risk factors. In addition, a recently published special safety analysis of cardiac events within the EORTC study of 942 patients with unresectable or metastatic GIST concluded that imatinib does not induce left ventricular failure in GIST patients where the observed rate was approximately 0.2% while it can be up to 2% in a population with pre-existing cardiac disease.

Skin Rashes and Severe Cutaneous Adverse Reactions

A generalized erythematous, maculopapular, pruritic skin rash has been reported that can fade despite continued therapy. Some patients may have pruritus without accompanying rash, and sometimes there is an exfoliative component. Re-exposure in some patients has resulted in reappearance of rash, but not in all patients. These eruptions generally respond to antihistamines and topical steroids. Occasionally, systemic steroids are required.

Skin rashes have been observed in up to one third of patients treated with imatinib across all indications. These are frequently pruritic and most commonly appear as erythematous, maculopapular or exfoliative lesions on the forearm, the trunk or the face or generalized with systemic expression. Skin biopsies have revealed a toxic drug reaction with a mixed cellular infiltrate. Although most rashes are mild and self-limiting more severe rare cases such as Stevens-Johnson toxic epidermal necrolysis, Erythema multiforme or DRESS may require interruption or discontinuation of treatment. Not surprisingly skin reactions were seen at a higher rate than placebo in the adjuvant GIST trial.

Hepatotoxicity

Hepatotoxicity, occasionally severe, may occur, and has been observed preclinically and clinically. LFT abnormalities usually consisted of mild elevations in transaminases, although a minority of patients had elevated levels of bilirubin. Onset is generally within the first two months of therapy, but has occurred as late as 6 to 12 months after commencing therapy. The levels generally normalize after withholding therapy for 1 to 4 weeks.

Hypophosphatemia

Low serum phosphate and hypophosphatemia (up to Grade 3 or 4) has been observed relatively commonly across all indications, however the origin and the clinical significance of this finding have not been established. Imatinib has been shown to inhibit the differentiation of human monocytes into osteoclasts. The decrease was accompanied by a decrease in the resorptive capacity of these cells. A dose-dependent decrease of RANK-L was observed in osteoclasts in the presence of imatinib. Sustained inhibition of osteoclastic activity may lead to counter regulatory response resulting in increased levels of PTH. The clinical relevance of the preclinical findings is yet unclear and an association with skeletal AEs such as bone fractures has not been demonstrated.

In the clinical development program serum phosphate was not routinely measured in all studies. Although it was initially hypothesized that hypophosphatemia might be dose-dependent, 24 month interpretable results from the Phase III TOPS study designed to investigate dose dependency of safety endpoints in patients with newly diagnosed CML, have shown that Grade 3 or 4 decreased serum phosphate or serum calcium has been experienced by 19.1% vs. 15.5% and 5.1% vs. 0.9% of patients receiving 400 mg and 800 mg, respectively.
Gastrointestinal Obstruction, Perforation or Ulceration
GI ulceration, which may represent in extreme cases local irritation by imatinib, has been observed in a small proportion of patients across all indications. Tumor hemorrhage/tumor necrosis, obstruction and GI perforation seem to be disease-related and have occurred exclusively or more frequently amongst GIST patients. In the case of metastatic GIST, tumor necrosis may occur in the context of tumor response, rarely leading to perforation. GI obstruction/ileus occurred most commonly in the GIST population where it may be caused by tumor obstruction from metastatic GIST and in the adjuvant setting by adhesions from previous GI surgery.

Tumor lysis syndrome
A causal relationship between tumor lysis syndrome and IMATIS treatment is deemed possible, although some cases were confounded by concomitant medications and other independent risks (see section 4.4).

Growth retardation in children
IMATIS appears to affect the stature of children, especially children who are pre-pubertal. A causal relationship between growth retardation in children and IMATIS treatment could not be ruled out although for some cases of growth retardation there was limited information. (see section 4.4).

Severe respiratory adverse drug reaction
Severe respiratory events, sometimes fatal, have been observed with IMATIS treatment, including acute respiratory failure, pulmonary hypertension, interstitial lung disease and pulmonary fibrosis. Pre-existing cardiac or pulmonary conditions that may be associated with severe respiratory events have been reported in many of these cases.

Laboratory test abnormalities

Hematology
CML-associated cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses ≥750 mg (phase I study). However, the occurrence of cytopenias was also clearly dependent on the stage of the disease. In patients with newly diagnosed CML, cytopenias were less frequent than in the other CML patients. The frequency of Grade 3 or 4 neutropenias (ANC <1.0×10^9/L) and thrombocytopenias (platelet count <50×10^9/L) being between 4 and 6 times higher in blast crisis and accelerated phase (59 to 64% and 44 to 63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia). In newly diagnosed chronic phase CML Grade 4 neutropenia (ANC <0.5×10^9/L) and thrombocytopenia (platelet count <10×10^9/L) were observed in 3.6% and <1% of patients, respectively. The median duration of the neutropenic and thrombocytopenic episodes usually ranged from 2 to 3 weeks, and from 3 to 4 weeks, respectively. These events can usually be managed with either a dose reduction or an interruption of treatment with IMATIS, but can in rare cases lead to permanent discontinuation of treatment. In pediatric CML patients the most frequent toxicities observed were Grade 3 or 4 cytopenias involving neutropenia, thrombocytopenia and anemia. These generally occur within the first several months of therapy.

In patients with unresectable or metastatic malignant GIST (study B2222), Grade 3 and 4 anemia’s were reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intratumoral bleeding in at least some of these patients. Grade 3 and 4 neutropenia were seen in 7.5% and 2.7% of patients, respectively, and Grade 3 thrombocytopenia in 0.7% of patients. No patient developed Grade 4 thrombocytopenia. The decreases in WBC and neutrophil counts occurred mainly during the first six weeks of therapy, with values remaining relatively stable thereafter.

Biochemistry
Severe elevation of transaminases (<5%) or bilirubin (<1%) has been seen in CML patients and was usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week) of IMATIS. Treatment was discontinued permanently because of liver laboratory abnormalities in less
than 1% of CML patients. In GIST patients (study B2222), 6.8% of Grade 3 or 4 SGPT (serum glutamic pyruvic transferase) elevations and 4.8% of Grade 3 or 4 SGOT (serum glutamic oxaloacetic transferase) elevations were observed. Bilirubin elevation was below 3%.

There have been cases of cytolytic and cholestatic hepatitis and hepatic failure; in some of which outcome was fatal.

**Reporting of suspected adverse reactions:**
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to Turkey Pharmacovigilance Centre (TÜFAM). (www.titck.gov.tr; e-mail: tufam@titck.gov.tr; phone number: 0 800 314 00 08; fax: 0 312 218 35 99)

4.9 **Overdose**
Experience with higher than therapeutic doses is limited. Isolated cases of IMATIS overdosage have been reported spontaneously and in the literature. Generally the reported outcome in these cases was improvement or recovery. In the event of overdosage the patient should be observed and appropriate symptomatic treatment should be given.

Events that have been reported at different dose ranges are as follows:

**Adult overdose**
1,200 to 1,600 mg (duration varying between 1 to 10 days): Nausea, vomiting, diarrhea, rash, erythema, edema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite. 1,800 to 3,200 mg (as high as 3,200 mg daily for 6 days): Weakness, myalgia, increased CPK, increased bilirubin, gastrointestinal pain. 6,400 mg (single dose): One case in the literature reported one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, neutrophil count decreased, increased transaminases. 8 to 10 g (single dose): Vomiting and gastrointestinal pain have been reported.

**Pediatric overdose**
One 3 year-old male exposed to a single dose of 400 mg experienced vomiting, diarrhea and anorexia and another 3 year old male exposed to a single dose of 980 mg dose experienced decreased white blood cell count and diarrhea.

For further advice on management of overdose please contact the National Poisons Information Centre (0800 POISON or 0800 764 766).

**Drug abuse and dependence**
Drug dependency, addiction and recreational abuse have not been reported as a problem with this compound.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

**Pharmacotherapeutic group:** protein-tyrosine kinase inhibitor

**ATC code:** LO1XE01

**Mechanism of Action:**
Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the BCR-ABL tyrosine kinase (TK), as well as several receptor TKs: KIT, the receptor for stem cell factor (SCF) coded for by the KIT proto-oncogene, the discoidin domain receptors (DDR1) and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta). Imatinib can also inhibit cellular events mediated by activation of these receptor kinases.
Imatinib is a protein-tyrosine kinase inhibitor, which potently inhibits the breakpoint cluster region-Abelson (BCR-ABL) tyrosine kinase at the in vitro, cellular, in vivo levels. The compound selectively inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukemia (ALL) patients. In colony transformation assays using ex vivo peripheral blood and bone marrow samples, imatinib shows selective inhibition of BCR-ABL positive colonies from CML patients. In vivo the compound shows anti-tumor activity as a single agent in animal models using BCRABL positive tumor cells.

Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), KIT, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating KIT mutation. Constitutive activation of the PDGFR or the Abl protein tyrosine kinases as a consequence of fusion to diverse partner proteins or constitutive production of PDGF have been implicated in the pathogenesis of MDS/MPD, HES/CML and DFSP. In addition, constitutive activation of KIT or the PDGFR has been implicated in the pathogenesis of SM. Imatinib inhibits signaling and proliferation of cells driven by dysregulated PDGFR, KIT and ABL kinase activity.

Clinical studies in CML
The effectiveness of IMATIS is based on overall hematological and cytogenetic response rates and progression free survival.

Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in advanced, blast or accelerated phase disease, other Ph+ leukemia’s or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy. One large, open-label, multicenter, international randomized phase III study has been conducted in patients with newly diagnosed Ph+ CML. In addition, children have been treated in two phase I studies and one open-label, multicenter, single arm phase II trial.

In all clinical studies 38 to 40% of patients were ≥60 years of age and 10 to 12% of patients were ≥70 years of age.

Chronic phase, newly diagnosed:
This phase III study compared treatment with either single-agent IMATIS or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C). Patients showing lack of response (lack of complete hematological response (CHR) at 6 months, increasing white blood cells (WBC), no major cytogenetic response (MCyR) at 24 months), loss of response (loss of CHR or McyR) or severe intolerance to treatment were allowed to crossover to the alternative treatment arm. In the IMATIS arm, patients were treated with 400 mg daily. In the IFN arm, patients were treated with a target dose of IFN of 5 MIU/m²/day subcutaneously in combination with subcutaneous Ara-C 20 mg/m²/day for 10 days/month.

A total of 1,106 patients have been randomized from 177 centers in 16 countries, 553 to each arm. Baseline characteristics were well balanced between the two arms. Median age was 51 years (range 18 to 70 years), with 21.9% of patients ≥60 years of age. There were 59% males and 41% females; 89.9% Caucasian and 4.7% black patients. At the cut-off for this analysis (7 years after the last patient had been recruited), the median duration of first-line treatment was 82 and 8 months in the IMATIS and IFN arm, respectively. The median duration of second-line treatment with IMATIS was 64 months. 60% of patients randomized to IMATIS are still receiving first-line treatment. In these patients, the average dose of IMATIS was 403±57 mg. Overall, in patients receiving first line IMATIS, the average daily dose delivered was 406±76 mg. As a consequence of a higher rate of both discontinuations and crossovers, only 2% of patients randomized to IFN are still on first line treatment. In the IFN arm, withdrawal of consent (14%) was the most frequent reason for discontinuation of first line therapy, and the most frequent reason for crossover to the IMATIS arm was severe intolerance to treatment (26%) and progression (14%). The primary efficacy endpoint of the study is progression-free survival. Progression was defined as any of the following event: progression to accelerated phase or blast crisis (AP/BC), death, loss of CHR or MCyR, or in patients not achieving a CHR an increasing WBC despite appropriate therapeutic management. Major cytogenetic response, hematological response, molecular response (evaluation of minimal residual disease), time to accelerated phase or blast crisis and survival are main secondary endpoints. Response data are shown in Table 3.
### Table 3 Response in newly diagnosed CML studies (84-month data)

<table>
<thead>
<tr>
<th>(Best response rates)</th>
<th>Imatinib n=553</th>
<th>IFN+Ara-C n=553</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematological response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHR rate n (%) [%95 confidence interval]</td>
<td>534 (96.6%)* 94.7%, 97.9%</td>
<td>313 (56.6%)* 52.4%, 60.8%</td>
</tr>
<tr>
<td><strong>Cytogenetic response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major response n (%) [%95 confidence interval]</td>
<td>490 (88.6%)* [85.7%, 91.1%]</td>
<td>129 (23.3%)* [19.9%, 27.1%]</td>
</tr>
<tr>
<td>Complete CyR n (%)</td>
<td>456 (82.5%)*</td>
<td>64 (11.6%)*</td>
</tr>
<tr>
<td>Partial CyR n (%)</td>
<td>34 (6.1%)</td>
<td>65 (11.8%)</td>
</tr>
<tr>
<td><strong>Molecular Response</strong>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major response at 12 months (%)</td>
<td>50.2%</td>
<td>9.6%</td>
</tr>
<tr>
<td>Major response at 24 months (%)</td>
<td>70.2%</td>
<td>25%</td>
</tr>
<tr>
<td>Major response at 84 months (%)</td>
<td>87.9%</td>
<td>75%</td>
</tr>
</tbody>
</table>

* p<0.001, Fischer's exact test
** Molar response percentages are based on available samples

**Hematological response criteria (all responses to be confirmed verified ≥4 weeks later):**
- Number of leucocytes <10×10⁹/L, number of platelets <450×10⁹/L, myelocyte+metamyelocyte <5% in blood, no blast cell or promyelocyte in blood, basophile <20%, no extramedullary involvement

**Cytogenetic response criteria:**
- Complete (0% Ph+ metaphases), partial (1-35%), minor (36-65%) or minimal (66-95%)
- Major response (0-35%), combines both complete and partial responses.

**Major molecular response criteria:**
- In the peripheral blood reduction of ≥3 logarithms in the amount of Bcr-Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardized baseline.

Rates of complete hematological response, major cytogenetic response and complete cytogenetic response on first-line treatment were estimated using the Kaplan-Meier approach, for which non-responders were censored at the date of last examination. Using this approach the estimated cumulative response rates for first-line treatment with Imatinib are shown in Table 4.

### Table 4 Estimated cumulative responses to first-line Imatinib

<table>
<thead>
<tr>
<th>Months on therapy</th>
<th>%CHR</th>
<th>%MCyR</th>
<th>%CCyR</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 months</td>
<td>96.4%</td>
<td>84.6%</td>
<td>69.5%</td>
</tr>
<tr>
<td>24 months</td>
<td>97.2%</td>
<td>89.5%</td>
<td>79.7%</td>
</tr>
<tr>
<td>36 months</td>
<td>97.2%</td>
<td>91.1%</td>
<td>83.6%</td>
</tr>
<tr>
<td>48 months</td>
<td>98.2%</td>
<td>91.9%</td>
<td>85.2%</td>
</tr>
<tr>
<td>60 months</td>
<td>98.4%</td>
<td>91.9%</td>
<td>86.7%</td>
</tr>
<tr>
<td>84 months</td>
<td>98.4%</td>
<td>91.9%</td>
<td>87.2%</td>
</tr>
</tbody>
</table>

For analysis of long-term outcomes patients randomized to receive Imatinib were compared with patients randomized to receive IFN. Patients who crossed over prior to progression were not censored at the time of crossover, and events that occurred in these patients following crossover were attributed to the original randomized treatment.

With 7 years follow-up, there were 93 (16.8%) progression events in the Imatinib arm: 37 (6.7%) involving progression to AP/BC, 31 (5.6%) loss of MCyR, 15 (2.7%) loss of CHR or increase in WBC and 10 (1.8%) CML unrelated deaths. In contrast, there were 165 (29.8%) events in the IFN+Ara-C arm of which 130 occurred during first-line treatment with IFN+Ara-C.

The estimated rate of progression-free survival at 84 months is 81.2% with 95% CI (78, 85) in the Imatinib arm and 60.6% (56.5) in the control arm (p <0.001) (Figure 1). The yearly rates of progression for Imatinib were 3.3% in the 1st year after start of study, 7.5% in the 2nd year and 4.8%, 1.7%, 0.8% 0.3% and 2.0% in
the 3rd, 4th, 5th, 6th and 7th year of study respectively.
The estimated rate of patients free of progression to accelerated phase or blast crisis at 84 months was significantly higher in the Imatinib arm compared to the IFN arm (92.5% versus 85.1%, p<0.001) (Figure 2). The annual rate of progression decreased with time on therapy: yearly rates of disease progression to accelerated phase or blast crisis were 1.5%, 2.8%, 1.6%, 0.9%, 0.5%, 0% and 0.4% in the first to seventh year, respectively.

Figure 1 Time to progression (ITT principle)

A total of 71 (12.8%) and 85 (15.4%) patients died in the Imatinib and IFN+Ara-C groups, respectively. At 84 months the estimated overall survival is 86.4% (83, 90) vs. 83.3% (80, 87) in the randomized Imatinib and the IFN+Ara-C groups, respectively (p=0.073, log-rank test). This time-to-event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to Imatinib. Additionally, a greater number of patients received bone marrow transplant (BMT) after discontinuation of study treatment in the IFN+Ara-C group (n=66, 38 after crossover to Imatinib) compared with the Imatinib group (n=50, 8 after crossover to IFN) at the 84 month update. When censoring the 48 deaths that occurred after BMT, the 84-months survival rates were 89.6 vs 88.1 (p=0.200, log-rank test). Only 31 deaths (before BMT) of the Imatinib patients (5.6%) were attributed to CML, compared to 40 of the IFN+Ara-C patients (7.2%). When only considering these CML-related deaths and censoring any deaths after BMT or due to other reasons, the estimated 84-months survival rates were 93.6% vs. 91.1% (p=0.1, log rank test). The effect of Imatinib treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported Imatinib data with the primary data from another Phase III study using IFN+Ara-C (n=325) in an identical regimen. In this publication, the superiority of Imatinib over IFN+Ara-C in overall survival was demonstrated (p<0.001); within 42 months, 47 (8.5%) Imatinib patients and 63 (19.4%) IFN+Ara-C patients had died.
The degree of cytogenetic response had a clear effect on long-term outcomes in patients on Imatinib. Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to AP/BC at 84 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 84 months (p<0.001 overall, p=0.25 between CCyR and PCyR). Based on the 18-months landmark, the estimates were 99%, 90% and 83% respectively, now also including a statistically significant difference between CCyR and PCyR (p<0.001).

Molecular monitoring represented important additional prognostic information. For patients with CCyR and reduction in BCR-ABL transcripts of at least 3 logarithms at 12 months, the probability of remaining progression free at 60 months was numerically greater when compared to patients who had CCyR but less than 3 log reduction (95% vs. 89%, p=0.068), and significantly greater than that observed for patients who were not in CCyR at 12 months (70%, p<0.001). Considering only progression to AP/BC, the estimated rates without event were 100%, 95% and 88% respectively (p<0.001 overall, p=0.007 between CCyR with and without MMR). Using the 18-months landmark, the estimated rates without AP/BC at 60 months were 100% for patients with CCyR and MMR, 98% for patients with CCyR but without MMR and only 87% for patients without CCyR (p<0.001 overall, p=0.105 between CCyR with and without MMR).

In this study, dose escalations were allowed from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily. After 42 months of follow-up, 11 patients who achieved a complete hematological response at 3 months and a major cytogenetic response at 12 months while on a daily dose of 400 mg experienced a confirmed loss (within 4 weeks) of their cytogenetic response. Of these 11 patients, 4 patients escalated up to 800 mg daily, 2 of whom regained a cytogenetic response (1 partial and 1 complete, the latter also achieving a molecular response), while of the 7 patients in whom the dose was not escalated, only one regained a complete cytogenetic response. The percentage of some ADRs was higher in the 40 patients in whom the dose was increased to 800 mg daily compared to the population of patients before dose increase (n=551). These more frequent ADRs included gastrointestinal hemorrhages, conjunctivitis and elevation of transaminases or bilirubin. Other ADRs were reported with lower or equal frequency.

Quality of Life was measured using the validated FACT-BRM instrument. All domains were assessed and reported significantly higher scores in the Imatinib arm compared to the IFN arm. QoL data showed that patients maintain their well-being while on treatment with Imatinib.

**Chronic phase, Interferon-failure:**

532 patients were treated at a starting dose of 400 mg. The patients were distributed in three main categories: hematological failure (29%), cytogenetic failure (35%), or intolerance to interferon (36%). Patients had received a median of 14 months of prior IFN therapy at doses ≥25 x10⁸ IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months. The primary efficacy variable of the study was the rate of major cytogenetic response (complete plus partial response, 0 to 35% Ph+ metaphases in the bone marrow).

In this study, 65% of the patients achieved a major cytogenetic response, which was complete in 53% of patients (Table 4). A complete hematological response was achieved in 95% of patients.

**Accelerated phase:**

235 patients with accelerated phase disease were enrolled. The first 77 patients were started at 400 mg, the protocol was subsequently amended to allow higher dosing and the remaining 158 patients were started at 600 mg.

The primary efficacy variable was the rate of hematological response, reported as either complete hematological response, no evidence of leukemia (i.e. clearance of blasts from the marrow and the blood, but without a full peripheral blood recovery as for complete responses), or return to chronic phase CML. A confirmed hematological response was achieved in 71.5% of patients (Table 5). Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% of patients. For the patients treated at 600 mg, the current estimates for median progression-free survival and overall survival were 22.9 and 42.5 months, respectively. In a multivariate analysis, a dose of 600 mg was associated with an improved time to progression, independent of platelet count, blood blasts and hemoglobin ≥10 g/L.

**Myeloid blast crisis:**
260 patients with myeloid blast crisis were enrolled. 95 (37%) had received prior chemotherapy for treatment of either accelerated phase or blast crisis (“pretreated patients”) whereas 165 (63%) had not (“untreated patients”). The first 37 patients were started at 400 mg, the protocol was subsequently amended to allow higher dosing and the remaining 223 patients were started at 600 mg.

The primary efficacy variable was the rate of hematological response, reported as either complete hematological response, no evidence of leukemia, or return to chronic phase CML using the same criteria as for the study in accelerated phase. In this study, 31% of patients achieved a hematological response (36% in previously untreated patients and 22% in previously treated patients). The rate of response was also higher in the patients treated at 600 mg (33%) as compared to the patients treated at 400 mg (16%, p=0.0220). The current estimate of the median survival of the previously untreated and treated patients was 7.7 and 4.7 months, respectively.

### Table 5 Response in CML studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Chronic phase IFN failure (n=532)</th>
<th>Accelerated phase (n=235)</th>
<th>Myeloid blast crisis (n=260)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematological response</strong></td>
<td>95% (92.3-96.3)</td>
<td>71% (65.3-77.2)</td>
<td>31% (25.2-36.8)</td>
</tr>
<tr>
<td>Complete hematological response (CHR)</td>
<td>95%</td>
<td>42%</td>
<td>8%</td>
</tr>
<tr>
<td>No evidence of leukemia (NEL)</td>
<td>-</td>
<td>12%</td>
<td>5%</td>
</tr>
<tr>
<td>Return to chronic phase (RTC)</td>
<td>-</td>
<td>17%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Major cytogenetic response</strong></td>
<td>65% (61.2-69.5)</td>
<td>28% (22.0-33.9)</td>
<td>15% (11.2-20.4)</td>
</tr>
<tr>
<td>Complete</td>
<td>53%</td>
<td>20%</td>
<td>7%</td>
</tr>
<tr>
<td>Partial</td>
<td>12%</td>
<td>7%</td>
<td>8%</td>
</tr>
</tbody>
</table>

1Hematological response criteria (all responses to be confirmed after ≥4 weeks):
- CHR: Study 0110 [WBC <10×10^9/L, platelets <450×10^9/L, myelocyte+metamyelocyte <5% in blood, no blasts and promyelocytes in blood, basophils <20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC ≥1.5×10^9/L, platelets ≥100×10^9/L, no blood blasts, BM blasts <5% and no extramedullary disease]
- NEL: Same criteria as for CHR but ANC ≥1×10^9/L and platelets ≥20×10^9/L (in studies 0102 and 0109)
- RTC: <15% blasts BM and PB, <30% blasts+promyelocytes in BM and PB, <20% basophils in PB, no extramedullary disease other than spleen and liver (in studies 0102 and 0109).

BM = bone marrow, PB = peripheral blood

2Cytogenetic response criteria:
- A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1-35%)

### Pediatric patients:
A total of 51 pediatric patients with newly diagnosed and untreated CML in chronic phase were enrolled in an open-label, multicentre, single arm phase II trial, and were treated with Imatinib 340 mg/m²/day. Imatinib treatment induced a rapid response in newly diagnosed pediatric CML patients with a CHR of 78% after 8 weeks of therapy and a complete cytogenetic response (CcyR) of 65% (comparable to results in adults) after 3 to 10 months of treatment.

A total of 31 heavily pre-treated pediatrics (45% with prior BMT and 68% with prior multiagent chemotherapy) with either chronic phase CML (n=15) or CML in blast crisis or Ph+ ALL (n=16) were enrolled in a dose-escalation phase I trial. Patients were treated at doses of Imatinib ranging between 260 mg/m²/day and 570 mg/m²/day. Out of 13 patients with CML and cytogenetic data available, 7 (54%) and 4 (31%) achieved a complete and partial cytogenetic response, respectively, for a rate of McyR of 85%.

### Clinical studies in Ph+ ALL
A total of 758 Ph+ ALL patients with either newly diagnosed or relapsed/refractory disease were enrolled in ten clinical studies, nine of which were uncontrolled and one randomized.

**Newly diagnosed Ph+ ALL**

In a controlled study (ADE10) of Imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, Imatinib used as single agent induced a significantly higher rate of complete hematological response than chemotherapy (96.3% vs. 50%; p=0.0001). When salvage therapy with Imatinib was administered in patients who did not respond or who responded poorly to chemotherapy, it resulted in 9 patients (81.8%) out of 11 achieving a complete hematological response. This clinical effect was associated with a higher reduction in BCR-ABL transcripts in the Imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02). All patients received Imatinib and consolidation chemotherapy after induction and the levels of BCR-ABL transcripts were identical in the two arms at 8 weeks. As expected on the basis of the study design, no difference was observed in remission duration, disease-free survival or overall survival, although patients with complete molecular response and remaining in minimal residual disease had a better outcome in terms of both remission duration (p=0.01) and disease-free survival (p=0.02). The results observed in a population of 211 newly diagnosed Ph+ ALL patients in four uncontrolled clinical studies (AAU02, ADE04, AJP01 and AUS01) are consistent with the results described above, as reported in Table 6. Imatinib in combination with chemotherapy induction resulted in a complete hematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients). The complete molecular response rate was 48% (49 out of 102 evaluable patients).

Similarly, in two uncontrolled clinical studies (AFR09 and AIT04) in which 49 newly diagnosed Ph+ ALL patients aged 55 years and over were given Imatinib combined with steroids with or without chemotherapy, there was a complete hematological response rate of 26% in 39 evaluable patients. Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p < 0.001; OS p < 0.01) in three studies (AJP01, AUS01 and AFR09).

**Table 6 Effect of Imatinib in newly diagnosed Ph+ ALL patient**

<table>
<thead>
<tr>
<th>Study</th>
<th>AAU02</th>
<th>ADE04</th>
<th>AJP01</th>
<th>AUS01</th>
<th>AFR09</th>
<th>AIT04</th>
<th>ADE10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Imatinib and CHT</td>
<td>Imatinib and CHT</td>
<td>Imatinib and CHT</td>
<td>Imatinib and CHT</td>
<td>Imatinib and CHT/steroids</td>
<td>Imatinib and steroids</td>
<td>Imatinib and CHT</td>
</tr>
<tr>
<td>N (evaluable for CHR)</td>
<td>12</td>
<td>45</td>
<td>80</td>
<td>21</td>
<td>29</td>
<td>18</td>
<td>27</td>
</tr>
<tr>
<td>CHR (%)</td>
<td>58</td>
<td>95</td>
<td>96</td>
<td>95</td>
<td>72</td>
<td>100</td>
<td>96</td>
</tr>
<tr>
<td>95% C.I.</td>
<td>28 - 85</td>
<td>85 - 99</td>
<td>89 - 99</td>
<td>76 - 100</td>
<td>53 - 87</td>
<td>82 - 100</td>
<td>81 - 100</td>
</tr>
<tr>
<td>CHR Historical controls [CHT]</td>
<td>51</td>
<td>61 - 94</td>
<td>61 - 94</td>
<td>29</td>
<td>29</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>(p&lt;0.0001)</td>
<td>(p&lt;0.01)</td>
<td>(p=0.003)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N (overall)</td>
<td>24</td>
<td>47</td>
<td>80</td>
<td>20</td>
<td>30</td>
<td>19</td>
<td>28</td>
</tr>
<tr>
<td>1-year DFS (%)</td>
<td>NA</td>
<td>NA</td>
<td>61±6</td>
<td>87</td>
<td>60</td>
<td>-</td>
<td>54</td>
</tr>
<tr>
<td>Median DFS (m)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1-year OS (%)</td>
<td>61±13*</td>
<td>NA</td>
<td>76±5</td>
<td>-</td>
<td>68</td>
<td>-</td>
<td>54</td>
</tr>
<tr>
<td>2-year OS (%)</td>
<td>-</td>
<td>NA</td>
<td>-</td>
<td>75**</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Median OS (m)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

CHR = complete hematological response
CHT = chemotherapy
m = months

NA = Not available
* p <0.01
§ after induction
** on the first 20 patients both newly diagnosed and relapse/refractory
& on all patients, including newly diagnosed, relapsed patients and CML blastic crisis
Relapsed/refractory Ph+ ALL
When Imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 66 out of 429 patients evaluable for response, in a hematological response rate of 33% (12% complete) and a major cytogenetic response rate of 23%. (Of note, out of the 429 patients, 353 were treated in an expanded access program without primary response data collected.) The median time to progression in the overall population of 429 patients with relapsed/refractory Ph+ ALL ranged from 1.9 to 3.1 months, and median overall survival in the 409 evaluable patients ranged from 5 to 9 months. In 14 patients, imatinib in combination with induction chemotherapy resulted in a complete hematological response rate of 92% in 12 evaluable patients and a major cytogenetic response rate of 100% in 8 evaluable patients. Molecular response was assessed in four patients, and two responded completely.

A population of 146 relapsed or refractory patients aged 55 years and over received Imatinib as monotherapy and were analyzed separately because of the lack of curative treatment. A total of 14 out of 146 patients were treated with Imatinib 600 mg daily and were evaluable for response; complete hematological response was observed in 5 patients (35%) and major cytogenetic response in 7 patients (50%). Of note, four patients who were treated with a lower dose of Imatinib (400 mg daily) did not respond, suggesting that this dose is insufficient. In the overall population of 146 patients, median disease-free survival ranged from 2.8 to 3.1 months and median overall survival from 7.4 to 8.9 months.

Clinical studies in MDS/MPD
One open label, multicentre, phase II clinical trial (study B2225) was conducted testing Imatinib in diverse populations of patients suffering from life-threatening diseases associated with ABL, KIT or PDGFR protein tyrosine kinases. This study included 7 patients with MDS/MPD out of a total of 185 patients treated, 45 of whom had hematological diseases and 140 a variety of solid tumors. These patients were treated with Imatinib 400 mg daily. The ages of the enrolled patients ranged from 20 to 86 years. A further 24 patients with MDS/MPD aged 2 to 79 years were reported in 12 published case reports and a clinical study. These patients also received Imatinib at a dose of 400 mg daily with the exception of three patients who received lower doses. Of the total population of 31 patients treated for MDS/MPD, 14 (45%) achieved a complete hematological response and 9 (29%) a complete cytogenetic response (39% including major and partial responses). Of note, the malignancy carried a translocation, usually involving the chromosome t5q33 or t4q12, resulting in a PDGFR gene re-arrangement in 14 evaluable patients. All of these responded hematologically (12 completely). Cytogenetic response was evaluated in 11 out of 14 patients, all of whom responded (9 patients completely). Only 2 (13%) out of the 16 patients without a translocation associated with PDGFR gene re-arrangement achieved a complete hematological response and one (6%) achieved a major cytogenetic response. A further patient with a PDGFR gene re-arrangement in molecular relapse after bone marrow transplant responded molecularly. Median duration of therapy was 12.9 months (0.8 to 26.7) in the 7 patients treated within study B2225 and ranged between 1 week and more than 18 months in responding patients in the published literature. Results are provided in Table 7.

<table>
<thead>
<tr>
<th>Table 7 Response in MDS/MPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (Number of patients)</td>
</tr>
<tr>
<td>Overall population</td>
</tr>
<tr>
<td>Chromosome t5 involved</td>
</tr>
<tr>
<td>Chromosome t4 involved</td>
</tr>
<tr>
<td>Others / no translocation</td>
</tr>
<tr>
<td>Molecular relapse</td>
</tr>
</tbody>
</table>

NE: Not evaluable

Clinical studies in SM
One open-label, multicentre, phase II clinical trial (study B2225) was conducted testing Imatinib in diverse populations of patients suffering from life-threatening diseases associated with ABL, KIT or PDGFR protein tyrosine kinases. This study included 5 patients with SM out of a total of 185 patients treated, 45 of whom...
had hematological diseases and 140 a variety of solid tumors. The SM patients were treated with Imatinib 100 mg to 400 mg daily. The ages of these patients ranged from 49 to 74 years. A further 25 patients with SM aged 26 to 85 years were reported in 10 published case reports and case series. These patients also received Imatinib at doses of 100 mg to 400 mg daily. Of the total population of 30 patients treated for SM, 10 (33%) achieved a complete hematological response and 9 (30%) a partial hematological response (63% overall response rate). Cytogenetic abnormalities were evaluated in 21 of the 30 patients treated in the published reports and in the study B2225. Eight out of these 21 patients had FIP1L1-PDGFR-alpha fusion kinase. Patients with this cytogenetic abnormality are most likely to be males and to have eosinophilia associated with their systemic mast cell disease. Two patients showed a KIT mutation in the juxta membrane region (one Phe522Cys and one K509I). Sixteen patients had unknown or no detected cytogenetic abnormality. Four patients showed a D816V mutation (the one responder had concomitant CML and SM). The majority of patients reported in the reviewed literature with the D816V KIT mutation are not considered sensitive to Imatinib. Median duration of therapy was 13 months (range 1.4-22.3 months) in the 5 patients treated within study B2225 and ranged between 1 month and more than 30 months in responding patients in the published literature. Results are provided in Table 8.

### Table 8 Response in SM

<table>
<thead>
<tr>
<th>Cytogenetic abnormality</th>
<th>Number of patients</th>
<th>Complete hematological response</th>
<th>Partial hematological response</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIP1L1-PDGFR-alpha fusion kinase (or CHIC2 deletion)</td>
<td>8</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Juxta membrane mutation</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Unknown or no cytogenetic abnormality detected</td>
<td>16</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>D816V mutation</td>
<td>4</td>
<td>1*</td>
<td>0</td>
</tr>
<tr>
<td>Overall totals</td>
<td>30</td>
<td>10 (33%)</td>
<td>9 (30%)</td>
</tr>
</tbody>
</table>

*Patient had concomitant CML and SM

### Clinical studies in HES/CEL

One open-label, multicentre, phase II clinical trial (study B2225) was conducted testing Imatinib in diverse populations of patients suffering from life-threatening diseases associated with ABL, KIT or PDGFR protein tyrosine kinases. In this study, 14 patients with HES/CEL out of a total of 185 patients (45 of whom had hematological diseases and 140 a variety of solid tumors) were treated with 100 mg to 1,000 mg of Imatinib daily. The ages of these patients ranged from 16 to 64 years. A further 162 patients with HES/CEL aged 11 to 78 years were reported in 35 published case reports and case series. These patients received Imatinib at doses of 75 mg to 800 mg daily. Of the total population of 176 patients treated for HES/CEL, 107 (61%) achieved a complete hematological response and 16 (9%) a partial hematological response (70% overall response rate). Cytogenetic abnormalities were evaluated in 117 of the 176 patients treated in the published reports and in the study B2225. Out of these 117 patients, 61 were positive for FIP1L1-PDGFR-alpha fusion kinase. All of these FIP1L1-PDGFR-alpha fusion kinase positive patients achieved a complete hematological response. The FIP1L1-PDGFR-alpha fusion kinase was either negative or unknown in 115 patients, of which 62 (54%) achieved either a complete (n=46) or partial (n=16) hematological response. Results are provided in Table 9.

### Table 9 Response in HES/CEL

<table>
<thead>
<tr>
<th>Cytogenetic abnormality</th>
<th>Number of patients</th>
<th>Complete hematological response</th>
<th>Partial hematological response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive FIP1L1-PDGFR-alpha fusion kinase</td>
<td>61</td>
<td>61</td>
<td>0</td>
</tr>
<tr>
<td>Negative FIP1L1-PDGFR-alpha fusion kinase</td>
<td>56</td>
<td>12</td>
<td>9</td>
</tr>
<tr>
<td>Unknown cytogenetic abnormality</td>
<td>59</td>
<td>34</td>
<td>7</td>
</tr>
<tr>
<td>Overall totals</td>
<td>176</td>
<td>107 (61%)</td>
<td>16 (9%)</td>
</tr>
</tbody>
</table>

Additionally, improvements in symptomatology and other organ dysfunction abnormalities were reported by
the investigators in the case reports. Improvements were reported in cardiac, nervous, skin/subcutaneous tissue, respiratory/thoracic/mediastinal, musculoskeletal/connective tissue/vascular, and gastrointestinal organ systems.

Clinical studies in unresectable or metastatic GIST

Two open-label, randomized, multinational Phase III studies (SWOG, EORTC) were conducted in patients with unresectable or metastatic malignant gastrointestinal stromal tumors (GIST). The design of these two studies were similar allowing a predefined combined analysis of safety and efficacy. A total of 1,640 patients were enrolled into the two studies and randomized 1:1 to receive either 400 mg or 800 mg orally q.d. continuously until disease progression or unacceptable toxicity. Patients in the 400 mg q.d. treatment group who experienced disease progression were permitted to crossover to receive treatment with 800 mg q.d. The studies were designed to compare response rates, progression free survival and overall survival between the dose groups. Median age at patient entry was 60 (range 17 to 94, 25th–75th age percentile 50 to 69). Males comprised 58% of the patients enrolled. All patients had a pathologic diagnosis of CD117 positive unresectable and/or metastatic malignant GIST.

The primary objective of the two studies was to evaluate either progression free survival (PFS) with a secondary objective of overall survival (OS) in one study (EORTC) or overall survival with a secondary objective of PFS in the other study (SWOG). A planned analysis of both OS and PFS from the combined datasets from these two studies was conducted. Results from this combined analysis are shown in Table 10.

<table>
<thead>
<tr>
<th>Table 10 Overall survival, Progression Free Survival and Tumor Response Rates in the Phase III GIST Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imatinib 400 mg N=818</td>
</tr>
<tr>
<td>Progression Free Survival (months) (50% median)</td>
</tr>
<tr>
<td>[95% CI]</td>
</tr>
<tr>
<td>Overall Survival (months)</td>
</tr>
<tr>
<td>[95% CI]</td>
</tr>
<tr>
<td>Best Overall Tumor Response</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*NC includes patients with unconfirmed responses, no change and lack of progressive disease

Median follow up for the combined studies was 37.5 months (25th – 75th percentile 19 to 46 months). There was a statistically significant improvement in PFS in the 800 mg treatment group (23.2 months [95% CI, 20.8 to 24.9]) compared to the 400 mg treatment group (18.9 months [95% CI, 17.4 to 21.2]) (p=0.03). However, there were no observed differences in overall survival between the treatment groups (p=0.98). The estimated overall PFS for all 1640 patients in these Phase III studies was 21 months [95% CI 19.4 to 22.5] and the estimated OS of 48.8 months [95% CI 46.3 to 51.6]. 5.1% of patients achieved a confirmed complete response and 47.5% achieved a partial response. Treatment at either dose level was generally well tolerated and overall 5.4% of patients withdrew due to toxicity.

Patients who crossed over following disease progression from the 400 mg/day treatment group to the 800 mg/day treatment (n=347) had a 3.4 month median and 7.7 month mean exposure to Imatinib following crossover. Overall survival of patients following crossover was 14.3 months [95% CI 12.2 to 16.7] and 19.3% of these patients were still alive at 48 months.

One phase II, open-label, randomized multinational study was conducted in patients with unresectable or metastatic malignant gastrointestinal stromal tumors (GIST). In this study 147 patients were enrolled and randomized to receive either 400 mg or 600 mg orally q.d. for up to 36 months. These patients ranged in age from 18 to 83 years and had a pathologic diagnosis of Kit-positive malignant GIST that was unresectable and/or metastatic.
The primary evidence of efficacy was based on objective response rates. Tumors were required to be measurable in at least one site of disease, and response characterization based on Southwestern Oncology Group (SWOG) criteria. In this study, 83% of the patients achieved either a complete response, partial response or stable disease. Results are provided in Table 11.

Table 11 Best tumor response in trial STIB2222 (GIST)

<table>
<thead>
<tr>
<th>All doses (N=147)</th>
<th>400 mg (n= 73)</th>
<th>600 mg (n=74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best response</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Complete response</td>
<td>1(0.7)</td>
<td></td>
</tr>
<tr>
<td>Partial response</td>
<td>98 (66.7)</td>
<td></td>
</tr>
<tr>
<td>Stable disease</td>
<td>23 (15.6)</td>
<td></td>
</tr>
<tr>
<td>Progressive disease</td>
<td>18 (12.2)</td>
<td></td>
</tr>
<tr>
<td>Not evaluable</td>
<td>5 (3.4)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (1.4)</td>
<td></td>
</tr>
</tbody>
</table>

There were no differences in response rates between the two dose groups. A significant number of patients who had stable disease at the time of the interim analysis achieved a partial response with longer treatment (median follow-up 31 months). Median time to response was 13 weeks (95% C.I. 12 to 23). Median time to treatment failure in responders was 122 weeks (95% C.I. 106 to 147), while in the overall study population it was 84 weeks (95% C.I. 71 to 109). The median overall survival has not been reached. The Kaplan-Meier estimate for survival after 36-month follow-up is 68% (Figure 3). Additionally, there is no difference in survival between patients achieving stable disease and partial response (Figure 4).

Figure 3 Kaplan-Meier estimate of overall survival since start of study by treatment

Hazard ratio: 0.852, Log rank test p=0.5537.
Clinical study in adjuvant GIST

In the adjuvant setting, Imatinib was investigated in a multicentre, double-blind, long-term, placebo controlled phase III study (Z9001) involving 773 patients. The ages of these patients ranged from 18 to 91 years. Patients were included who had a histologic diagnosis of primary GIST expressing KIT protein by immunochemistry and a tumor size ≥3 cm in maximum dimension, with complete gross resection of primary GIST within 14 to 70 days prior to registration. After resection of primary GIST, patients were randomized to one of the two arms: Imatinib at 400 mg/day or matching placebo for one year.

The primary endpoint of the study was recurrence free survival (RFS) defined as the time from date of randomization to the date of recurrence or death from any cause.

Imatinib prolonged significantly RFS with 75% of patients being recurrence-free at 38 months in the Imatinib group vs 20 months in the placebo group (95% CIs, [30 non-estimable]; [14 nonestimable], respectively); (hazard ratio =0.398 [0.259 to 0.610], p<0.0001). At one year the overall RFS was significantly better for Imatinib (97.7%) vs. placebo (82.3%), (p<0.0001) therefore reducing the risk of recurrence by approximately 89% as compared with placebo (hazard ratio =0.113 [0.049 to 0.264]).

A second open label phase III study (SSG XVIII/AIO) compared 400 mg/day Imatinib 12 months treatment vs. 36 months treatment in patients after surgical resection of GIST and one of the following: tumor diameter >5 cm and mitotic count >5/50 high power fields (HPF); or tumor diameter >10 cm and any mitotic count or tumor of any size with mitotic count >10/50 HPF or tumors ruptured into the peritoneal cavity. There were a total of 397 patients consented and randomized to the study (199 patients on 12 month arm and 198 patients on 36 month arm), median age was 61 years (range 22 to 84 years). The median time of follow-up was 54 months (from date of randomization to data cut-off), with a total of 83 months between the first patient randomized and the cut-off date.

The primary endpoint of the study was recurrence free survival (RFS) defined as the time from date of randomization to the date of recurrence or death from any cause.

Thirty-six (36) months of Imatinib treatment significantly prolonged RFS compared to 12 months of Imatinib treatment (with overall Hazard Ratio (HR) =0.46 [0.32, 0.65], p<0.0001 and a HR of 0.42 [0.28, 0.61] beyond month 12) (Table 12, Figure 5). There were 84 (42%) and 50 (25%) total RFS events for the 12-months and 36 months arms respectively.

In addition, thirty-six (36) months of Imatinib treatment significantly prolonged overall survival (OS) compared to 12 months of Imatinib treatment (HR=0.45 [0.22, 0.89], p=0.0187) (Table 12, Figure 6). The total number of deaths were 25 for the 12-months treatment arm and 12 for the 36-months treatment arm.
Table 12 12-month and 36-month Imatinib Treatment (SSGXVIII/AIO Trial)

<table>
<thead>
<tr>
<th></th>
<th>12-month treatment arm % (CI)</th>
<th>36-month treatment arm % (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 mos.</td>
<td>93.7 (89.2-96.4)</td>
<td>95.9 (91.9-97.9)</td>
</tr>
<tr>
<td>24 mos.</td>
<td>75.4 (68.6-81.0)</td>
<td>90.7 (85.6-94)</td>
</tr>
<tr>
<td>36 mos.</td>
<td>60.1 (52.5-66.9)</td>
<td>86.6 (80.8-90.8)</td>
</tr>
<tr>
<td>48 mos.</td>
<td>52.3 (44.0-59.8)</td>
<td>78.3 (70.8-84.1)</td>
</tr>
<tr>
<td>60 mos.</td>
<td>47.9 (39.0-56.3)</td>
<td>65.6 (56.1-73.4)</td>
</tr>
</tbody>
</table>

Survival

<table>
<thead>
<tr>
<th></th>
<th>36 mos.</th>
<th>48 mos.</th>
<th>60 mos.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>94.0 (89.5-96.7)</td>
<td>87.9 (81.1-92.3)</td>
<td>81.7 (73.0-87.8)</td>
</tr>
<tr>
<td></td>
<td>96.3 (92.4-98.2)</td>
<td>95.6 (91.2-97.8)</td>
<td>92.0 (85.3-95.7)</td>
</tr>
</tbody>
</table>

Figure 5 Kaplan-Meier estimates for primary recurrence-free survival endpoint (ITT population)

Figure 6 Kaplan-Meier estimates for overall survival (ITT population)
Clinical studies in DFSP

One open label, multicentre, phase II clinical trial (study B2225) was conducted testing Imatinib in a diverse populations of patients suffering from life-threatening diseases associated with ABL, KIT or PDGFR protein tyrosine kinases. This study included 12 patients with DFSP out of a total of 185 patients, 45 of whom had hematological diseases and 140 a variety of solid tumors. The primary evidence of efficacy for patients in the solid tumor group was based on objective response rates. The solid tumor population was treated with Imatinib 800 mg daily. The age of the DFSP patients ranged from 23 to 75 years; DFSP was metastatic, locally recurrent following initial resective surgery and not considered amenable to further resective surgery at the time of study entry. A further 6 DFSP patients treated with Imatinib are reported in 5 published case reports, their ages ranging from 18 months to 49 years. The total population treated for DFSP comprises 18 patients, 8 of them with metastatic disease. The adult patients reported in the published literature were treated with either 400 mg (4 cases) or 800 mg (1 case) Imatinib daily. The pediatric patient received 400 mg/m²/day, subsequently increased to 520 mg/m²/day. Responses to treatment are described in Table 13.

Table 13 Response rate in 18 DFSP patients treated with imatinib

<table>
<thead>
<tr>
<th>Tumor response</th>
<th>Number of patients</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>7</td>
<td>39</td>
</tr>
<tr>
<td>Partial response *</td>
<td>8</td>
<td>44</td>
</tr>
<tr>
<td>Total</td>
<td>15</td>
<td>83</td>
</tr>
</tbody>
</table>
* 5 patients made disease free by surgery

Twelve of these 18 patients either achieved a complete response (7 patients) or were made disease free by surgery after a partial response (5 patients, including one child) for a total complete response rate of 67%. A further 3 patients achieved a partial response, for an overall response rate of 83%. Of the 8 patients with metastatic disease, five responded (62%), three of them completely (37%). The median duration of therapy in study B2225 was 6.2 months, with a maximum duration of 24.3 months, while in the published literature it ranged between 4 weeks and more than 20 months.

Clinical studies in hepatic insufficiency

In a study of patients with varying degrees of hepatic dysfunction (mild, moderate and severe - see Table 14 below for liver function classification), the mean exposure to imatinib (dose normalized AUC) did not increase compared to patients with normal liver function. In this study, 500 mg daily was safely used in patients with mild liver dysfunction and 300 mg daily was used in other patients. Although only a 300 mg daily dose was used in patients with moderate and severe liver dysfunction, pharmacokinetic analysis projects that 400 mg can be used safely (see sections 4.2, 4.4, 4.8 and 5.2).

Table 14 Liver function classification

<table>
<thead>
<tr>
<th>Liver dysfunction</th>
<th>Liver function tests</th>
</tr>
</thead>
</table>
| Mild              | Total bilirubin = 1.5 ULN  
AST: >ULN (can be normal or <ULN if total bilirubin is >ULN) |
| Moderate          | Total bilirubin: 1.5 – 3.0 ULN  
AST: Any value |
| Severe            | Total bilirubin: >3 – 10 ULN  
AST: Any value |

ULN = Upper limit of normal for the institution;  
AST = aspartate aminotransferase

Clinical studies in renal insufficiency

In a study of patients with varying degrees of renal dysfunction (mild, moderate and severe - see Table 15 below for renal function classification), the mean exposure to imatinib (dose normalized AUC) increased 1.5- to 2-fold compared to patients with normal renal function, which corresponded to an elevated plasma level of AGP, a protein to which imatinib binds strongly. No correlation between imatinib exposure and the severity of renal deficiency was observed. In this study, 800 mg daily was safely used in patients with mild
renal dysfunction and 600 mg daily was used in moderate renal dysfunction. The 800 mg dose was not tested in patients with moderate renal dysfunction due to the limited number of patients enrolled. Similarly, only 2 patients with severe renal dysfunction were enrolled at the low (100 mg) dose, and no higher doses were tested. No patients on hemodialysis were enrolled in the study. Literature data showed that a daily dose of 400 mg was well tolerated in a patient with endstage renal disease on hemodialysis. The PK plasma exposure in this patient fell within the range of values of imatinib and its metabolite CGP74588 observed in patients with normal renal function. Dialysis was not found to intervene with the plasma kinetics of imatinib. Since renal excretion represents a minor elimination pathway for imatinib, patients with severe renal insufficiency and on dialysis could receive treatment at the 400 mg starting dose. However, in these patients caution is recommended. The dose can be reduced if not tolerated, or increased for lack of efficacy (see sections 4.2, 4.4, 4.8 and 5.2).

<table>
<thead>
<tr>
<th>Renal insufficiency</th>
<th>Renal function tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>CrCL = 40-59 ml/minute</td>
</tr>
<tr>
<td>Moderate</td>
<td>CrCL = 20-39 ml/minute</td>
</tr>
<tr>
<td>Severe</td>
<td>CrCL = &lt;20 ml/minute</td>
</tr>
</tbody>
</table>

5.2 Pharmacokinetic properties
The pharmacokinetics of IMATIS have been evaluated over a dosage range of 25 to 1,000 mg. Plasma pharmacokinetic profiles were analyzed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.

Absorption
Mean absolute bioavailability for imatinib is 98%. The coefficient of variation for plasma imatinib AUC is in the range of 40 to 60% after an oral dose. When given with a high fat meal, the rate of absorption of imatinib was minimally reduced (11% decrease in C\text{max} and prolongation of t\text{max} by 1.5 h), with a small reduction in AUC (7.4%) compared to fasting conditions.

Distribution
At clinically relevant concentrations of imatinib, binding to plasma proteins was approximately 95% on the basis of in vitro experiments, mostly to albumin and alpha-acid-glycoprotein, with little binding to lipoprotein.

Metabolism
The main circulating metabolite in humans is the N-demethylated piperazine derivative (CGP71588), which shows similar in vitro potency as the parent compound. The plasma AUC for this metabolite was found to be only 16% of the AUC for imatinib. The plasma protein binding of the N-demethylated metabolite is similar to that of the parent compound.

Elimination
Based on the recovery of compound(s) after an oral 14C-labeled dose of imatinib, approximately 81% of the dose was eliminated within 7 days in feces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% feces), the remainder being metabolites.

Plasma pharmacokinetics
Following oral administration in healthy volunteers, the t½ was approximately 18 h, suggesting that once-daily dosing is appropriate. The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25 to 1,000 mg imatinib after oral administration. There was no change in the kinetics of imatinib on repeated dosing, and accumulation was 1.5 - to 2.5-fold at steady state when dose once daily.
Population pharmacokinetics
Based on population pharmacokinetic analysis, there was a small effect of age on the volume of distribution (12% increase in patients >65 years old). This change is not thought to be clinically significant. The effect of body weight on the clearance of imatinib is such that for a patient weighing 50 kg the mean clearance is expected to be 8.5 L/h, while for a patient weighing 100 kg the clearance will rise to 11.8 L/h. These changes are not considered sufficient to warrant dose adjustment based on kg bodyweight. There is no effect of gender on the kinetics of imatinib.

Further population PK analysis in the phase III study in newly diagnosed CML patients showed that the effect of covariates and co-medications on both clearance and volume of distribution appears to be small and is not sufficiently pronounced to warrant dose adjustment.

Pharmacokinetics in children
As in adult patients, imatinib was rapidly absorbed after oral administration in pediatric patients in both phase I and phase II studies. Dosing in children at 260 and 340 mg/m² achieved the same exposure, respectively, as doses of 400 mg and 600 mg in adult patients. The comparison of AUC(0-24) on Day 8 and Day 1 at 340 mg/m² dose level revealed a 1.7-fold drug accumulation after repeated once daily dosing.

Organ function impairment
Imatinib and its metabolites are not excreted via the kidney to a significant extent. Patients with mild and moderate impairment of renal function appear to have a higher plasma exposure than patients with normal renal function. The increase is approximately 1.5- to 2-fold, corresponding to a 1.5-fold elevation of plasma AGP, to which imatinib binds strongly. The free drug clearance of imatinib is probably similar between patients with renal impairment and those with normal renal function, since renal excretion represents only a minor elimination pathway for imatinib (see sections 4.2, 4.4 and 5.1).

Although the results of pharmacokinetic analysis showed that there is considerable inter-subject variation, the mean exposure to imatinib did not increase in patients with varying degrees of liver dysfunction as compared to patients with normal liver function (see sections 4.2, 4.4, 4.8 and 5.1).

5.3 Preclinical safety data
Imatinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity and reproductive toxicity studies. Target organs associated with the pharmacological action of imatinib include bone marrow, peripheral blood, lymphoid tissues, gonads and gastrointestinal tract. Other target organs include the liver and the kidney. Imatinib was embryotoxic and teratogenic in rats. Fertility was not affected in the preclinical fertility and early embryonic development study although lower testes and epididymal weights appear to have a higher plasma exposure than the recommended dose of 340 mg/day, respectively, and 0.4 to 3.0 times the daily exposure in children (based on AUC) at 340 mg/m². The

The papilloma/carcinoma of the preputial/clitoral gland were noted at 30 and 60 mg/kg/day, representing approximately 0.5 to 4 or 0.3 to 2.4 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 0.4 to 3.0 times the daily exposure in children (based on AUC) at 340 mg/m². The
renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumors of the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted at 60 mg/kg/day. The relevance of these findings in the rat carcinogenicity study for humans is not known. An analysis of the safety data from clinical trials and spontaneous adverse event reports did not provide evidence of an increase in overall incidence of malignancies in patients treated with imatinib compared to that of the general population. Non-neoplastic lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth. The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

**Tablet core**
- Cellulose microcrystalline (PH 101)
- Hydroxypropyl methylcellulose (HPMC) E3
- Cellulose microcrystalline (PH 102)
- Crospovidone (Kollidon CL)
- Colloidal silicon dioxide (Aerosil 200)
- Magnesium stearate

**Film coating [Opadry II Orange (85F230022)]**
- Polyvinyl alcohol
- Polyethylene glycol (Macrogol)/PEG 3350
- Yellow iron oxide
- Talc
- Titanium dioxide
- Red iron oxide

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
24 months

6.4 Special precautions for storage
Store below 30°C. Store in the original package. Keep out of the reach and sight of children.

6.5 Nature and contents of container
Imatis 100 mg film-coated tablet: Packs containing 20 and 60 film-coated tablets in PVC blisters.
Imatis 400 mg film-coated tablet: Packs containing 10 and 30 film-coated tablets in PVC blisters.

6.6 Special precautions for disposal and other handling
Any unused material should be disposed according to local disposal regulations.

7. MEDICINE SCHEDULE

Prescription Medicine

8. SPONSOR
9. DATE OF FIRST APPROVAL

Date of first authorization:  15/05/2014

10. DATE OF REVISION OF THE TEXT

07/06/2017